Taken together, our findings suggest a potential use of the three genes Cxcl11, Gbp2b, and Ido1 as a signature for myeloid cell activation in whole tumor tissue and will be further investigated as a clinical prognostic biomarker for melanoma patients. The gene discussed is IDO1; the disease is neoplasm.